预约演示

更新于：2025-05-16

Cetirizine Hydrochloride

盐酸西替利嗪

更新于：2025-05-16

概要

基本信息

简介盐酸西替利嗪是一种小分子药物，通过作为H1受体拮抗剂来靶向H1受体。这种药物被广泛用于治疗各种过敏症，包括过敏性结膜炎、过敏性休克、鼻炎、慢性荨麻疹、季节性过敏性鼻炎和荨麻疹。盐酸西替利嗪由强生公司研制，于1991年首次获批用于医疗。通过阻止H1受体，该药物有助于防止组胺的结合，组胺是引起许多过敏反应症状的罪魁祸首。虽然该药物通常耐受良好，但一些患者可能会出现嗜睡或口干等副作用。总的来说，盐酸西替利嗪仍然是治疗各种过敏症的高效药物。

药物类型

小分子化药

别名

Cetirizien Hydrochloride Drops、Cetirizine、Cetirizine Dihydrochloride

+ [46]

靶点

H1 receptor

作用方式

拮抗剂

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

免疫系统疾病感染眼部疾病+ [3]

在研适应症

季节性过敏性鼻炎变应性结膜炎皮炎+ [8]

非在研适应症

急性结膜炎慢性荨麻疹特应性皮炎+ [3]

原研机构

Johnson & Johnson

在研机构

Teva UK Ltd.Pfizer Canada ULC苏州欧康维视生物科技有限公司

+ [7]

非在研机构

Johnson & Johnson Holdco (NA), Inc.

GSK PlcJohnson & Johnson de Colombia SA

+ [8]

权益机构

Apotex, Inc.ITROM Pharmaceutical Group

Santen Pharmaceutical Co., Ltd.

+ [12]

最高研发阶段批准上市

首次获批日期

加拿大 (1991-12-31),

过敏性鼻炎荨麻疹

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C21H26Cl2N2O3

InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N

CAS号83881-52-1

关联

114

项与盐酸西替利嗪相关的临床试验

NCT06890260

/ RecruitingN/AIIT

A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis

Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.

开始日期2025-04-11

申办/合作机构

浙江医院

CTRI/2024/08/072453

/ Recruiting临床3期

A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL

开始日期2024-08-20

申办/合作机构

Akums Drugs & Pharmaceuticals Ltd.

[+1]

NCT06819774

/ Recruiting临床3期

Efficacy and Safety of Cetirizine Hydrochloride Injection in the Treatment of Acute Urticaria: a Randomized, Double-blind, Positive Controlled, Multicenter Phase III Clinical Study

The objective of this study was to evaluate the efficacy and safety of cetirizine hydrochloride injection in the treatment of acute urticaria.The participants were randomized to receive cetirizine hydrochloride or diphenhydramine hydrochloride.

开始日期2024-04-22

申办/合作机构

山东新时代药业有限公司

100 项与盐酸西替利嗪相关的临床结果

登录后查看更多信息

100 项与盐酸西替利嗪相关的转化医学

登录后查看更多信息

100 项与盐酸西替利嗪相关的专利（医药）

登录后查看更多信息

3,786

项与盐酸西替利嗪相关的文献（医药）

2025-08-01·FOOD CHEMISTRY

Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)

Article

作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming

This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.

2025-07-03·ANALYTICAL LETTERS

Development of Highly Sensitive Voltammetric Methods for the Determination of Antihistamine Drug Cetirizine Using A Poly(Bromocresol Purple) Film-Based Electrochemical Sensor

作者: Kul, Dilek ; Reis, Hamit Ali ; Sofu, Ümran ; Öztürk, Gökçe ; Erdemir, Fatih

Simple and highly sensitive voltammetric methods were developed using a poly(bromocresol purple) modified glassy carbon electrode to quantify cetirizine.Poly(bromocresol purple) film was synthesized on the surface of a glassy carbon electrode by cyclic voltammetry for 50 potential cycles in 0.1 M phosphate buffer at pH 6.0 containing 5.0 x 10-4 M of the monomer.Quantification of cetirizine exhibiting irreversible properties using the optimized conditions with a linear dependence between cetirizine concentration and peak currents from 0.2 to 100 μM for differential pulse voltammetry (DPV) and 0.1 to 100 μM for square wave voltammetry (SWV).Detection limits were 21.8 and 15.1 nM for DPV and SWV, resp.Relative standard deviation (RSD) values below 0.98% indicated good precision.Recovery values from 100.12% to 100.90% with relative standard deviations below 1.14% for DPV and SWV in pharmaceutical formulations and urine samples demonstrated the high accuracy of the developed methods.The prepared modified electrode exhibited good fabrication reproducibility and suitable long-term stability.Finally, no interferences were observed in cetirizine determination in the presence of co-existing substances in the biol. samples.

2025-07-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice

Article

作者: Sasaki, Akiko ; Baba, Yuta ; Yoshimura, Kiyoshi ; Tsunoda, Takuya ; Shimane, Toshikazu ; Nakashima, Rie ; Maruyama, Yuki ; Sasaki, Aya ; Shida, Midori ; Kuramasu, Atsuo ; Tsuji, Mayumi ; Toyoda, Hitoshi ; Hosonuma, Masahiro ; Tsurui, Toshiaki ; Funayama, Eiji ; Tajima, Kohei ; Kiuchi, Yuji

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy remains limited in inflammation-associated tumors, necessitating combinatorial approaches. Although combinations with cytotoxic or targeted agents are well established, the therapeutic potential of non-oncologic drugs, such as antihistamines, is less explored. In this study, we investigate whether cetirizine, a non-sedating histamine H₁ receptor antagonist, enhances the antitumor effects of anti-programmed cell death protein 1 (PD-1) antibody in a murine model of colitis-associated colorectal cancer. Combination therapy, not monotherapy, significantly reduced tumor volume in vivo. Flow cytometry of splenocytes revealed increased PD-1 expression on T cells only in the combination group, suggesting systemic immune activation. Immunohistochemical analysis showed elevated CD3⁺ T-cell infiltration into tumors following combination treatment. Meanwhile, gene expression analysis of tumor tissues revealed downregulated Vegfa, Mmp9, Il10, and Cd80, along with upregulated Hspg2 and Fn1, suggesting a shift in the tumor microenvironment. In vitro, cetirizine suppressed Mmp9 expression in CT26 cells, Il10 in macrophages, and VEGFA in human umbilical vein endothelial cells, indicating cell-type-specific effects that partially mirror the in vivo findings. Immunohistochemistry further demonstrated a reduced frequency of FoxP3⁺ regulatory T cells among CD3⁺ T cells within the tumor stroma in the combination group. Collectively, these findings indicate that cetirizine enhances ICI efficacy by reshaping the tumor microenvironment through immunomodulatory mechanisms. Our results support the repurposing of antihistamines as a novel strategy to improve cancer immunotherapy.

237

项与盐酸西替利嗪相关的新闻（医药）

2025-05-14

·GlobeNewswire-Health Care

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogsEpiscleral venous pressure changes did not show a trend vs. placeboSafety profile is consistent with that of the first Phase 3 trial, Mont BlancNCX 470 intraocular pressure lowering efficacy and safety have already been demonstrated in the Phase 3 glaucoma trial, Mont BlancTimeline and planning for New Drug Application submissions remain on track May 14, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the results of the Whistler Phase 3b exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering in healthy volunteers and ocular hypertensive patients.“We believe that the outcomes in favor of NCX 470 in several trabecular meshwork aqueous humour dynamics parameters are due to nitric oxide. These positive exploratory results suggest that further investigation may be warranted into the dual mechanism effect of NCX 470 on intraocular pressure.” said Doug Hubatsch, Chief Scientific Officer of Nicox. “The therapeutic characteristics of NCX 470 demonstrated in the Phase 3 program so far shows that we have an approvable and differentiated asset with a promising clinical profile. We look forward to announcing the safety and efficacy results from our ongoing Phase 3 trial, Denali, expected in the third quarter of this year.” The Whistler Phase 3b exploratory trial was a double-masked, placebo-controlled study designed to further our understanding of the action of NCX 470 ophthalmic solution, 0.1%, on various aqueous humor dynamic parameters in 18 healthy volunteers or subjects with ocular hypertension. Measurements were taken at baseline and after 8 days at 1 pm and, for some parameters, at 3 pm. Changes in aqueous humor flow rate trended towards significance vs. placebo (p=0.072). Outflow facility was positive at 1 pm (p=0.081), significant at 3 pm (p=0.001), as was the diurnal outflow (p=0.004). We believe this change is due to the effect of nitric oxide on the trabecular meshwork1. IOP lowering and uveoscleral outflow were statistically significant at all timepoints measured, whilst episcleral venous pressure did not show a notable trend. These findings support the dual mechanism of action for IOP lowering of NCX 470 through both the conventional (nitric oxide-stimulated) and the uveoscleral (prostaglandin-stimulated) pathways. The safety profile observed was consistent with that of the first Phase 3 trial, Mont Blanc. The Whistler trial was an exploratory trial and is not a requirement for the submission of New Drug Applications for NCX 470 and therefore does not impact the development timeline. The patient population in the Whistler trial was primarily normotensive healthy volunteers with mean baseline IOPs of 16.6 mmHg and 16.9 mmHg for NCX 470 and placebo treated patients, respectively. This is not the same patient profile as in the Phase 3 glaucoma program. Safety and efficacy have already been demonstrated in the first Phase 3 clinical trial, Mont Blanc. The results of the Mont Blanc trial are available on the Company’s website, www.nicox.com. About NCX 470NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last American patient in Denali has completed their final visit, with Chinese patients completing theirs, and the results are expected in Q3 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China, where NCX 470 is exclusively licensed to Ocumension Therapeutics. NCX 470 is also licensed exclusively to Kowa for Japan. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 For examples of the role of nitric oxide on these parameters, see Dismuke WM, Liang J, Overby DR, Stamer WD. Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. Exp Eye Res. 2014;120:28–35 and Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci. 1994;35:2515–2520. Attachment EN_WhistlerResultsMay2025_PR_FINAL

临床3期临床结果

2025-04-30

·GlobeNewswire-Health Care

Nicox Provides Full Year 2024 Financial Results

Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus CapitalNicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is currently financed into the fourth quarter of 2025 Topline results from NCX 470 second Phase 3 clinical trial, Denali, expected in the third quarter of 2025Ongoing discussions and business development outreach underway for NCX 470 U.S. partnership April 30, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided its financial results for the full year of 2024, as approved by the Board of Directors on 28 April 2025, and provided an update on key future milestones. Following the sale of the VYZULTA royalty in October 2024, the Company will no longer be providing quarterly revenue reports.“The achievements of 2024 by the Nicox team and our partners have allowed us to keep our product development on track and prepared to deliver two clinical readouts on NCX 470 in 2025. Our focus is now on ensuring that the Company is in the optimal position to exploit those results through ongoing partnership, business and corporate development discussions.” said Gavin Spencer, Chief Executive Officer of Nicox.Key Future Milestones Whistler Phase 3b clinical trial investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: Results are expected in May 2025. Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: Topline results are expected in the third quarter of 2025.   Full Year 2024 Financial Results for Nicox SARevenue for the full year of 2024 was €7.9 million versus €6.9 million for the full year of 2023, including €3.0 million of VYZULTA royalties, recognized up to 30 June 2024 prior to the sale of the royalties to Soleus Capital, versus €6.6 million, consisting principally of royalty payments, for the full year of 2023. The revenue for 2024 also includes the upfront payment of €3.0 million from Kowa for the Japanese rights to NCX 470 and a non-cash amount of €1.5 million previously recognized as prepaid income. The revenue for 2024 also includes €0.2 million of internal rebilling compared to €0.3 million for 2023.Operating expenses for the full year of 2024 were €18.7 million compared to €24.2 million for the full year of 2023.Exceptional income in 2024 was €13.7 million compared to €0.1 million in 2023. In 2024 this revenue corresponds to the sale of the future milestones and royalty of VYZULTA to Soleus Capital.Nicox SA recorded a net loss of €22.4 million for year ended 31 December 2024, compared to a net loss of €20.9 million for the same period in 2023. The 2024 loss includes a non-cash amount of €27.1 million due to the impairment of an intercompany receivable held by Nicox SA on its U.S. affiliate Nicox Ophthalmics, Inc. The recoverability of this receivable depends on the future royalties the subsidiary is expected to receive from the commercialization of ZERVIATE. In accordance with French GAAP, the Company has adopted a prudent approach based on the most conservative sales forecast amongst other, more favorable scenarios. This led to a downward revaluation of the value of ZERVIATE following a new analysis for the Chinese market. This analysis highlighted developments that reduce the probability of achieving the initially anticipated annual peak sales target of US$100M. Since ZERVIATE is the sole revenue-generating asset in Nicox Ophthalmics, Inc., the intercompany receivable has consequently been impaired. The details concerning this impairment are given in Note 2.4.1 of the statutory accounts of the Company which are available on the Company’s website on the page “Financial and Regulatory Information”.As of 31 December 2024, Nicox SA had cash and cash equivalents of €10.5 million compared to €11.3 million as of 31 December 2023. The Company is currently funded until at least into the fourth quarter of 2025, based on focusing exclusively on the development of NCX 470. As of 31 December 2024, Nicox SA had financial debt of €15.1 million, consisting of €14.2 million in the form of a bond financing agreement with Kreos Capital (an affiliate of BlackRock), and a €0.9 million credit agreement guaranteed by the French State, and granted in the context of the COVID-19 pandemic. The Company is pursuing business development discussions, including the sale or license of certain assets, and exploring multiple other strategic options which could further extend the cash runway. The Company is evaluating all options for financing and will use the most appropriate at the time. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Income Statement (in thousands of euros)December 31, 2024December 31, 2023 Sales of services - misc. Chargeback3,315257Patent royalties4,5446,646 REVENUE7,8596,903 Reversals of depreciation, amortization, provisions, expense transfers45313Other income from ordinary activities574225 TOTAL OPERATING INCOME8,8867,141 Other purchases and external expenses(14,552)(18,406)Taxes, duties and similar payments (other than on income)(72)(99)Salaries and wages(2,092)(1,764)Social charges(660)(739)Depreciation and amortisation of tangible and intangible assets(17)(21)Provision of expenses for risks and charges(12)(122)Other expenses(1,335)(3,046) TOTAL OPERATING EXPENSES(18,740)(24,197) OPERATING PROFIT (LOSS)(9,854)(17,056) Other interest and similar income8451,099Income from participating interests3,050-Reversal of provisions and transfer of expenses1339Foreign exchange gains371117 TOTAL FINANCIAL INCOME4,2791,255 Amortization, depreciation and financial provisions(27,776)(3,743)Interest and similar expenses(1,557)(1,633)Foreign exchange loss(45)(244) TOTAL FINANCIAL EXPENSES(29,378)(5,621) FINANCIAL PROFIT (LOSS)(25,099)(4,366) PRE-TAX LOSS(34,952)(21,422) Exceptional income on management operations13,74363Exceptional income on capital operations3- EXCEPTIONAL INCOME13,74663 Exceptional charges on management operations(2)-Exceptional charges on capital operations(922)- EXCEPTIONAL EXPENSES(924)- EXCEPTIONAL INCOME (LOSS)12,82263 Research Tax Credit(259)478 NET PROFIT & LOSS(22,390)(20,881) Balance sheet (in thousands of euros)December 31, 2024December 31, 2023 ASSETS Intangible assets1324Property, plant and equipment1126Financial assets7251,805 TOTAL FIXED ASSETS7491,855 Trade receivables and related accounts1,6433,424Other receivables9,34934,323Cash and cash equivalents10,54211,259Prepaid expenses1,515886 TOTAL CURRENT ASSETS23,04949,893 Unrealized foreign exchange losses and valuation differences - Assets1313Bond redemption premiums6101,218 TOTAL REGULARISATION ACCOUNTS6231,231 TOTAL ASSETS24,42152,980 LIABILITIES Issued Capital69250,170Share premium533,549529,478Retained earnings(508,438)(537,354)Net loss for the period(22,390)(20,881) TOTAL SHAREHOLDERS' EQUITY3,41321,413 Provisions for liabilities1313Provisions for charges268700 TOTAL PROVISIONS FOR LIABILITIES AND CHARGES281713 Loans and debts from lending institutions15,06420,895Loans and other financial debts824,258Accounts payable and related accounts1,6512,499Tax and social security liabilities603648Deferred income7351,919 TOTAL LIABILITIES18,13530,218 Unrealized foreign exchange gains and valuation differences - Liabilities2,592635 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY24,42152,980 Attachment EN_FY2024_PR_FINAL

财报临床3期引进/卖出

2025-04-13

·信狐药迅

天士力引进重磅孤儿药PXT3003治疗1A型腓骨肌萎缩症提交上市申请|新受理（4.7-4.13）

本周药品注册受理数据，分门别类呈现，一目了然。(4.7-4.13）新药上市申请药品名称企业注册分类受理号PXT3003江苏天士力帝益药业有限公司2.3CXHS2500027冻干人用狂犬病疫苗(无血清Vero细胞)艾美荣誉(宁波)生物制药有限公司2.2CXSS2500044新药临床申请药品名称企业注册分类受理号抗菌肽PL-3301口腔凝胶江苏普莱医药生物技术有限公司1CXHL2500381抗菌肽PL-3301口腔凝胶江苏普莱医药生物技术有限公司1CXHL2500380HRS-8829注射用浓溶液北京盛迪医药有限公司1CXHL2500379艾本那肽注射液常山凯捷健生物药物研发(河北)有限公司1CXHL2500378HRS-9821吸入粉雾剂广东恒瑞医药有限公司1CXHL2500377注射用TFX05-01浙江扬厉医药技术有限公司1CXHL2500373注射用SBK009成都施贝康生物医药科技有限公司1CXHL2500372VS-2218固体分散体片唯久生物技术(苏州)有限公司1CXHL2500369VS-2218固体分散体片唯久生物技术(苏州)有限公司1CXHL2500368DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500376DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500375TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500371TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500370WEYZ-1乳膏南京韦尔优众医药有限公司1CXHL2500365DAT-1604片北京丹擎医药科技有限公司1CXHL2500364DAT-1604片北京丹擎医药科技有限公司1CXHL2500363XLH01片山东润中药业有限公司1CXHL2500367XLH01片山东润中药业有限公司1CXHL2500366IGP-14068-TM片杭州英创医药科技有限公司1CXHL2500361IGP-14068-TM片杭州英创医药科技有限公司1CXHL2500360177Lu-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL250035968Ga-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL2500358JMHT05湖南九典制药股份有限公司2.1;2.2CXHL2500357JMHT05湖南九典制药股份有限公司2.1;2.2CXHL2500356LN2222山东新时代药业有限公司2.2CXHL2500384LN2222山东新时代药业有限公司2.2CXHL2500383BCM957上海云晟研新生物科技有限公司2.2CXHL2500362盐酸羟钴胺注射液石药集团中奇制药技术(石家庄)有限公司2.4CXHL2500382舒沃替尼片迪哲(江苏)医药股份有限公司2.4CXHL2500374重组带状疱疹疫苗(CHO细胞)安徽智飞龙科马生物制药有限公司1.3CXSL2500282四价肠道病毒灭活疫苗(Vero细胞)国药中生生物技术研究院有限公司1.4CXSL2500283注射用RGL-232上海瑞宏迪医药有限公司1CXSL2500295CRG-B191注射液上海科锐克医药科技有限公司1CXSL2500293XKH001注射液浙江鑫康合生物医药科技有限公司1CXSL2500292XKH001注射液浙江鑫康合生物医药科技有限公司1CXSL2500291PM1300注射用冻干制剂珠海普米斯生物科技有限公司1CXSL2500290QX029N注射液江苏荃信生物医药股份有限公司1CXSL2500288注射用HY0001a四川汇宇海玥医药科技有限公司1CXSL2500294LNF2102注射液山东新时代药业有限公司1CXSL2500287SCG101-V自体T细胞注射液星源德生物医药(上海)有限公司1CXSL2500286注射用QLS32015齐鲁制药有限公司1CXSL2500285MSLN-CAR-T细胞注射液上海怡豪生物科技有限公司1CXSL2500281舒欣瑞纳注射液江苏贵琼药业有限公司1CXSL2500280KM1溶瘤痘苗病毒注射液深圳市华药康明生物药业有限责任公司1CXSL2500274KSD-101注射液中山恒赛生物科技有限公司1CXSL2500273注射用LY4101174礼来苏州制药有限公司1CXSL2500272JD012-CEL注射液北京景达生物科技有限公司1CXSL2500276注射用ZG006苏州泽璟生物制药股份有限公司1CXSL2500279注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2500278注射用SKB315四川科伦博泰生物医药股份有限公司1CXSL2500270注射用SSGJ-612沈阳三生制药有限责任公司1CXSL2500269SSGJ-707注射液沈阳三生制药有限责任公司1CXSL2500268CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2500275重组抗IL-1β人源化单克隆抗体注射液三生国健药业(上海)股份有限公司1CXSL2500267注射用TQB6411正大天晴药业集团南京顺欣制药有限公司1CXSL2500266QL2109注射液齐鲁制药有限公司2.2CXSL2500284塔戈利单抗注射液四川科伦博泰生物医药股份有限公司2.2CXSL2500271仿制药申请药品名称企业注册分类受理号多种维生素注射液(13)辽宁海思科制药有限公司3CYHS2501413硫代硫酸钠注射液湖北成健药业有限公司3CYHS2501410注射用乳糖酸红霉素海南倍特药业有限公司3CYHS2501408二硫化硒洗剂江苏迪赛诺制药有限公司3CYHS2501404乙酰半胱氨酸片广州仁恒医药科技股份有限公司3CYHS2501401复方聚乙二醇(3350)电解质散合肥源丰顺医药科技有限公司3CYHS2501398聚乙二醇4000散成都恒瑞制药有限公司3CYHS2501395吡拉西坦注射液亚邦医药股份有限公司3CYHS2501394维生素K1注射液海南全盈药业有限公司3CYHS2501407盐酸美金刚口服溶液重庆赛诺生物药业股份有限公司3CYHS2501406布美他尼注射液合肥源丰顺医药科技有限公司3CYHS2501389盐酸多巴胺注射液广东南国药业有限公司3CYHS2501384盐酸多巴胺注射液广东南国药业有限公司3CYHS2501383琥珀酸亚铁片浙江赛默制药有限公司3CYHS2501379塞来昔布片昆明源瑞制药有限公司3CYHS2501388米诺膦酸片安徽博诺美科生物医药有限公司3CYHS2501386磷苯妥英钠注射用浓溶液南京正大天晴制药有限公司3CYHS2501342磷苯妥英钠注射用浓溶液南京正大天晴制药有限公司3CYHS2501341盐酸多巴胺注射液山东达冠医药科技有限公司3CYHS2501357盐酸多巴胺注射液山东达冠医药科技有限公司3CYHS2501355碳酸氢钠血滤置换液(无钾、无钙、0.6mmol/L镁)成都青山利康药业股份有限公司3CYHS2501352碳酸氢钠血滤置换液(钾2mmol/L 无钙)成都青山利康药业股份有限公司3CYHS2501350黄体酮注射液(Ⅱ)广州白云山明兴制药有限公司3CYHS2501363卢立康唑乳膏广东华润顺峰药业有限公司3CYHS2501361氯化钙注射液信合援生制药股份有限公司3CYHS2501356碳酸氢钠血滤置换液成都青山利康药业股份有限公司3CYHS2501351复方聚乙二醇(3350)电解质散西藏奥斯必秀医药有限公司3CYHS2501336磷酸奥司他韦颗粒广东瑞兴医药股份有限公司3CYHS2501318乳酸钠林格冲洗液上海长征富民金山制药有限公司3CYHS2501332伏格列波糖口腔崩解片山东朗诺制药有限公司3CYHS2501331盐酸曲唑酮片安徽省先锋制药有限公司3CYHS2501328苯磺酸氨氯地平口服溶液山东则正医药技术有限公司3CYHS2501327注射用苯唑西林钠成都晶富医药科技有限公司3CYHS2501324注射用苯唑西林钠成都晶富医药科技有限公司3CYHS2501323注射用苯唑西林钠成都晶富医药科技有限公司3CYHS2501322帕拉米韦注射液广州一品红制药有限公司3CYHS2501319西格列汀二甲双胍缓释片石药集团欧意药业有限公司3CYHS2501354西格列汀二甲双胍缓释片石药集团欧意药业有限公司3CYHS2501353阿昔洛韦钠注射液山东达冠医药科技有限公司3CYHS2501313阿昔洛韦钠注射液山东达冠医药科技有限公司3CYHS2501312维生素K滴剂重庆万霖生物医药科技有限公司3CYHS2501309艾拉莫德片南京臣功制药股份有限公司4CYHS2501420依折麦布片南京海鲸药业股份有限公司4CYHS2501419氟比洛芬凝胶贴膏河南羚锐制药股份有限公司4CYHS2501418沙库巴曲缬沙坦钠片山东鲁抗医药集团赛特有限责任公司4CYHS2501417沙库巴曲缬沙坦钠片山东鲁抗医药集团赛特有限责任公司4CYHS2501416沙库巴曲缬沙坦钠片山东鲁抗医药集团赛特有限责任公司4CYHS2501415依折麦布阿托伐他汀钙片(II)江西施美药业股份有限公司4CYHS2501414依折麦布阿托伐他汀钙片(I)江西施美药业股份有限公司4CYHS2501412盐酸奥洛他定滴眼液广东南国药业有限公司4CYHS2501411注射用醋酸亮丙瑞林微球浙江圣兆药物科技股份有限公司4CYHS2501409维生素B12滴眼液苏州乐珠制药有限公司4CYHS2501405沙库巴曲缬沙坦钠片华北制药股份有限公司4CYHS2501403沙库巴曲缬沙坦钠片华北制药股份有限公司4CYHS2501402非奈利酮片江苏诚康药业有限公司4CYHS2501400非奈利酮片江苏诚康药业有限公司4CYHS2501399美司钠注射液广州瑞尔医药科技有限公司4CYHS2501397非奈利酮片天津汉瑞药业有限公司4CYHS2501396乌帕替尼缓释片石药集团中诺药业(石家庄)有限公司4CYHS2501393盐酸西替利嗪滴剂成都华宇制药有限公司4CYHS2501392盐酸西替利嗪滴剂成都华宇制药有限公司4CYHS2501391熊去氧胆酸胶囊湖南千金协力药业有限公司4CYHS2501387蛋白琥珀酸铁口服溶液山东鲁抗医药集团赛特有限责任公司4CYHS2501385米格列醇片成都倍特药业股份有限公司4CYHS2501381蛋白琥珀酸铁口服溶液湖南九典制药股份有限公司4CYHS2501378艾普拉唑肠溶片安徽长江药业有限公司4CYHS2501377富马酸伏诺拉生片济南明鑫制药股份有限公司4CYHS2501376富马酸伏诺拉生片济南明鑫制药股份有限公司4CYHS2501375注射用头孢哌酮钠舒巴坦钠/氯化钠注射液湖南科伦制药有限公司4CYHS2501374注射用头孢哌酮钠舒巴坦钠/氯化钠注射液湖南科伦制药有限公司4CYHS2501373阿达帕林凝胶成都市海通药业有限公司4CYHS2501372酒石酸美托洛尔片湖南春光九汇现代中药有限公司4CYHS2501371酒石酸美托洛尔片湖南春光九汇现代中药有限公司4CYHS2501370依达拉奉右莰醇注射用浓溶液上海凯宝新谊(新乡)药业有限公司4CYHS2501390达格列净片苏州第壹制药有限公司4CYHS2501382达格列净片苏州第壹制药有限公司4CYHS2501380艾普拉唑肠溶片山东鲁抗医药集团赛特有限责任公司4CYHS2501362奥美沙坦酯片云鹏医药集团有限公司4CYHS2501349瑞舒伐他汀依折麦布片(Ⅰ)湖南尚众合生物医药有限公司4CYHS2501347富马酸依美斯汀滴眼液成都普什制药有限公司4CYHS2501346达格列净二甲双胍缓释片(III)复星医药(徐州)有限公司4CYHS2501345达格列净二甲双胍缓释片(I)复星医药(徐州)有限公司4CYHS2501344盐酸莫西沙星滴眼液安徽康融药业有限公司4CYHS2501340比索洛尔氨氯地平片国药集团容生制药有限公司4CYHS2501339硫酸镁钠钾口服用浓溶液湖北海美纳医药科技有限公司4CYHS2501365头孢地尼颗粒浙江巨泰药业有限公司4CYHS2501364注射用亚胺培南西司他丁钠海南丰恺思制药有限公司4CYHS2501360达格列净二甲双胍缓释片(I)四川美大康药业股份有限公司4CYHS2501359达格列净二甲双胍缓释片(IV)四川美大康药业股份有限公司4CYHS2501358硫酸氨基葡萄糖胶囊金鸿药业股份有限公司4CYHS2501348艾拉莫德片湖南明瑞制药股份有限公司4CYHS2501369来特莫韦片浙江海正药业股份有限公司4CYHS2501368盐酸米诺环素胶囊杭州和康药业有限公司4CYHS2501367盐酸米诺环素胶囊杭州和康药业有限公司4CYHS2501366富马酸伏诺拉生片海南海灵化学制药有限公司4CYHS2501338富马酸伏诺拉生片海南海灵化学制药有限公司4CYHS2501337富马酸伏诺拉生片苏州中化药品工业有限公司4CYHS2501335他达拉非片吉林金恒制药股份有限公司4CYHS2501317他达拉非片吉林金恒制药股份有限公司4CYHS2501316盐酸达泊西汀片河南君善生物技术有限公司4CYHS2501315盐酸达泊西汀片河南君善生物技术有限公司4CYHS2501314磷酸芦可替尼片上海创诺制药有限公司4CYHS2501334注射用右兰索拉唑湖南赛隆药业有限公司4CYHS2501333盐酸二甲双胍缓释片山东济坤生物制药有限公司4CYHS2501330盐酸二甲双胍缓释片山东济坤生物制药有限公司4CYHS2501329氧(气态)安康市汉滨区秦安气体制售中心4CYHS2501326罗替高汀贴片北京福元医药股份有限公司4CYHS2501325氧榆林市榆阳区聚源制氧厂4CYHS2501320来特莫韦注射液上海欣峰制药有限公司4CYHS2501343瑞舒伐他汀依折麦布片(Ⅰ)山东鲁抗医药集团赛特有限责任公司4CYHS2501321恩格列净片山东鑫齐药业有限公司4CYHS2501301恩格列净片山东鑫齐药业有限公司4CYHS2501300美阿沙坦钾片海南葫芦娃药业集团股份有限公司4CYHS2501311美阿沙坦钾片海南葫芦娃药业集团股份有限公司4CYHS2501310左卡尼汀注射液湖南赛隆药业(长沙)有限公司4CYHS2501308地屈孕酮片合肥国高药业有限公司4CYHS2501307布瑞哌唑片宜昌人福药业有限责任公司4CYHS2501306布瑞哌唑片宜昌人福药业有限责任公司4CYHS2501305布瑞哌唑片宜昌人福药业有限责任公司4CYHS2501304注射用伏立康唑以岭万洲国际制药有限公司4CYHS2501303普拉洛芬滴眼液中国大冢制药有限公司4CYHS2501302镥[177Lu]氧奥曲肽注射液迈得诺医疗科技集团有限公司3CYHL2500076酮洛芬凝胶贴膏湖南派格兰药业有限公司3CYHL2500078复方硫酸钠片山西振东安欣生物制药有限公司3CYHL2500075艾考糊精腹膜透析液青岛力腾医药科技有限公司4CYHL2500079噻托溴铵吸入粉雾剂艾特美(苏州)医药科技有限公司4CYHL2500077茚达特罗格隆溴铵吸入粉雾剂长风药业股份有限公司4CYHL2500074吸附破伤风疫苗远大赛威信生命科学(南京)有限公司3.3CXSL2500296人凝血因子IX远大蜀阳生命科学(成都)有限公司3.2CXSL2500277人生长激素注射液亿帆医药(上海)有限公司3.3CXSL2500289进口申请药品名称企业注册分类受理号Imlunestrant 片Eli Lilly Nederland B.V.1JXHS2500045Imlunestrant片Eli Lilly Nederland B.V.1JXHS2500044英克司兰钠注射液Novartis Europharm Limited2.4JXHS2500043注射用阿帕达酶αTakeda Pharmaceuticals U.S.A., Inc.3.1JXSS2500044注射用阿帕达酶αTakeda Pharmaceuticals U.S.A., Inc.3.1JXSS2500043盐酸替洛利生片Square Pharmaceuticals PLC.5.2JYHS2500019盐酸替洛利生片Square Pharmaceuticals PLC.5.2JYHS2500018BI 690517片Boehringer Ingelheim International GmbH1JXHL2500073BI 690517片Boehringer Ingelheim International GmbH1JXHL2500072Casdatifan 片Arcus Biosciences, Inc.1JXHL2500076BI1815368 片Boehringer Ingelheim International GmbH1JXHL2500075BI1815368 片Boehringer Ingelheim International GmbH1JXHL2500074Lartesertib片剂Merck Healthcare KGaA1JXHL2500071Tuvusertib片剂Merck Healthcare KGaA1JXHL2500070Tuvusertib片剂Merck Healthcare KGaA1JXHL2500069Tuvusertib胶囊Merck Healthcare KGaA1JXHL2500068Tuvusertib胶囊Merck Healthcare KGaA1JXHL250006721价肺炎球菌多糖结合疫苗Sanofi Pasteur Inc.1.4JXSL2500058VAY736注射液Novartis Pharma AG1JXSL2500057MEDI5752AstraZeneca AB1JXSL2500056ABBV-324注射用粉末AbbVie Inc.1JXSL2500055DS-1062aASTRAZENECA AB1JXSL2500054Isatuximab注射液(皮下注射)Sanofi-Aventis Recherche & Développement2.1JXSL2500053中药相关申请药品名称企业注册分类受理号三贝苎鼾胶囊浙江宝仁堂药业有限公司1.1CXZS2500016开心散安徽华润金蟾药业有限公司3.1CXZS2500015健脾解毒丸新疆维吾尔自治区中医医院1.1CXZL2500021注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

孤儿药疫苗申请上市

100 项与盐酸西替利嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00664	盐酸西替利嗪	R06AE07	DB00341

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
变应性结膜炎	美国	Harrow, Inc.	2017-05-30
皮炎	日本	UCB Japan Co. Ltd.	1998-06-30
湿疹	日本	UCB Japan Co. Ltd.	1998-06-30
瘙痒	日本	UCB Japan Co. Ltd.	1998-06-30
过敏	中国	苏州东瑞制药有限公司	1998-01-01
鼻炎	中国	苏州东瑞制药有限公司	1998-01-01
慢性荨麻疹	美国	Johnson & Johnson de Colombia SA	1995-12-08
常年性变应性鼻炎	美国	Johnson & Johnson de Colombia SA	1995-12-08
季节性过敏性鼻炎	美国	Johnson & Johnson de Colombia SA	1995-12-08
过敏性鼻炎	加拿大	Pfizer Canada ULC	1991-12-31
荨麻疹	加拿大	Pfizer Canada ULC	1991-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结膜炎	申请上市	韩国	SAMIL PHARMACEUTICAL Co., Ltd.	-
急性荨麻疹	临床3期	美国	JDP Therapeutics LLC	2013-07-01
急性荨麻疹	临床3期	加拿大	JDP Therapeutics LLC	2013-07-01
急性结膜炎	临床3期	美国	Nicox Ophthalmics, Inc.	2012-03-01
特应性皮炎	临床3期	-	GSK Plc	2005-08-01
皮肤真菌病	临床3期	-	GSK Plc	2005-08-01
季节性鼻炎	临床2期	加拿大	UCB Pharma GmbH	2006-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06039137 (H1-Switch Study, Pubmed \| JCO Oncol Pract)	N/A	-	-	Intravenous Clemastine	觸衊顧廠簾顧網衊顧鹹(壓願襯顧襯繭憲齋衊鹽) = 鏇鹽鬱構憲獵襯夢淵獵網鬱糧網繭齋製廠鏇壓 (窪膚願簾願獵觸蓋艱鹽, -3.4 ~ 1.1)	积极	2024-06-07
				Oral Cetirizine	觸衊顧廠簾顧網衊顧鹹(壓願襯顧襯繭憲齋衊鹽) = 蓋網簾蓋鑰衊網構壓繭網鬱糧網繭齋製廠鏇壓 (窪膚願簾願獵觸蓋艱鹽, -3.4 ~ 1.1)
NCT02023164 (CTgov)	临床3期	急性荨麻疹	36	JDP-205 Injection (Test Drug)	鏇製醖襯築窪簾壓獵餘(遞艱憲廠淵糧艱夢蓋襯) = 壓築獵窪範繭膚製蓋獵鹹蓋遞鑰鑰膚淵築齋夢 (夢壓衊鹽膚襯遞製積獵, 0.61) 更多	-	2024-02-09
				Diphenhydramine (Control)	鏇製醖襯築窪簾壓獵餘(遞艱憲廠淵糧艱夢蓋襯) = 襯鹹膚範糧積積夢衊製鹹蓋遞鑰鑰膚淵築齋夢 (夢壓衊鹽膚襯遞製積獵, 0.89) 更多
NCT02865018 (CTgov)	临床1/2期	视神经脊髓炎	16	cetirizine	構衊製淵選築選構艱顧(壓鬱醖網夢壓餘衊鹽鏇) = 網網遞顧願繭膚夢窪膚鹹構醖糧築膚鹽齋艱積 (憲壓繭壓觸網艱廠範壓, 0.80) 更多	-	2023-06-07
PRECEPT (ECTRIMS2022)	临床3期	-	20	Cetirizine 10mg	願襯範簾觸簾艱淵簾鬱(鹽憲鑰積範範糧糧醖糧) = 簾觸顧糧廠築襯夢襯積築膚範構膚艱壓糧選齋 (齋蓋積範淵製鬱餘繭鬱 )	积极	2022-10-12
				Diphenhydramine 25mg	願襯範簾觸簾艱淵簾鬱(鹽憲鑰積範範糧糧醖糧) = 窪網餘膚壓鏇齋鏇蓋窪築膚範構膚艱壓糧選齋 (齋蓋積範淵製鬱餘繭鬱 )
NCT04189588 (versus, CTgov)	临床2期	超敏反应 \| 肿瘤	34	Cetirizine HCl 10 mg/mL+Paclitaxel+Rituximab (Cohort A)	齋願醖醖製鹹衊壓壓範 = 簾顧選艱鏇襯鑰鹹襯觸廠鑰淵壓廠窪糧淵醖餘 (淵憲積夢積壓鏇廠餘壓, 鏇鬱衊壓願憲膚餘憲夢 ~ 醖餘襯鑰繭鏇夢網製願) 更多	-	2022-05-17
				Paclitaxel+Diphenhydramine 50 mg/mL+Rituximab (Cohort B)	齋願醖醖製鹹衊壓壓範 = 艱積夢選鹽選獵積餘襯廠鑰淵壓廠窪糧淵醖餘 (淵憲積夢積壓鏇廠餘壓, 網廠齋鹹鏇簾壓遞簾獵 ~ 餘積淵構夢壓繭簾襯築) 更多
NCT04189588 (ASCO2021)	临床2期	超敏反应	34	IV cetirizine 10 mg	襯選蓋膚夢網顧築艱選(獵網膚窪鬱膚構築衊襯) = 鹽製糧壓鹽夢襯鹽壓齋衊餘簾齋願觸窪蓋衊顧 (簾鬱願壓製蓋糧膚鹽構 ) 更多	-	2021-05-28
				IV diphenhydramine 50 mg	襯選蓋膚夢網顧築艱選(獵網膚窪鬱膚構築衊襯) = 築襯選製鑰觸鹹觸糧簾衊餘簾齋願觸窪蓋衊顧 (簾鬱願壓製蓋糧膚鹽構 ) 更多
NCT02935699 (Pubmed \| Ann Emerg Med)	临床3期	急性荨麻疹	262	Intravenous Cetirizine 10 mg	鏇積積壓願膚遞網鹽繭(廠範鹽範淵簾遞構積憲) = 襯簾製糧窪築糧獵醖餘網鏇壓網構鹽簾構觸遞 (鬱廠鹹觸網齋艱膚衊範 ) 更多	积极	2020-07-08
				Intravenous Diphenhydramine 50 mg	鏇積積壓願膚遞網鹽繭(廠範鹽範淵簾遞構積憲) = 蓋醖構構憲繭齋襯願範網鏇壓網構鹽簾構觸遞 (鬱廠鹹觸網齋艱膚衊範 ) 更多
NCT03192488 (CTgov)	临床4期	缺氧	13	Cetirizine (Cetirizine and Hypoxia)	獵遞願積窪糧醖觸膚鹹(蓋艱網觸積範廠鹹觸鹹) = 簾構窪鹽積選鹽築鹽齋襯淵繭構鏇憲鏇網構艱 (顧簾鹹鏇廠選膚膚積鑰, 1.92) 更多	-	2020-06-16
				Placebo (Placebo and Hypoxia)	獵遞願積窪糧醖觸膚鹹(蓋艱網觸積範廠鹹觸鹹) = 餘願糧築鹹遞範窪餘觸襯淵繭構鏇憲鏇網構艱 (顧簾鹹鏇廠選膚膚積鑰, 2.87) 更多
NCT02935699 (CTgov)	临床3期	急性荨麻疹	262	Test Drug (JDP-205) (Test Drug)	獵觸淵醖衊餘繭廠艱網(鹹齋衊壓醖醖鹽醖糧鑰) = 積觸顧壓製顧製築鹽餘網淵鹽製蓋構衊憲製顧 (積觸繭選製遞壓鏇選醖, 0.944) 更多	-	2019-11-27
				Active Control (Diphenhydramine) (Control)	獵觸淵醖衊餘繭廠艱網(鹹齋衊壓醖醖鹽醖糧鑰) = 窪鏇鬱壓窪顧鬱膚獵糧網淵鹽製蓋構衊憲製顧 (積觸繭選製遞壓鏇選醖, 0.984) 更多
NCT01825655 (CTgov)	临床4期	瘙痒	3	Cetirizine (Cetirizine)	鑰壓顧壓窪鏇網築顧蓋(構範齋願製製衊簾遞網) = 糧構範鹽廠窪餘鑰顧襯遞選鏇廠簾觸窪顧襯襯 (糧衊襯繭壓遞製窪廠鑰, 鏇餘壓觸願顧艱壓鹹遞 ~ 艱網遞製顧範壓製製製) 更多	-	2018-09-11
				Placebo or sugar pill (Sugar Pill)	鬱構觸鹹衊遞鏇積鏇鑰(鏇顧壓淵範蓋廠醖廠觸) = 積積築窪鬱願膚夢蓋衊餘夢積鑰淵餘淵壓觸網 (願顧襯製鬱顧鬱築願窪, 鏇積簾網壓膚積鑰範憲 ~ 築廠顧鹹積壓鬱蓋餘壓) 更多